anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Recently the efficacy of repetitive Transcranial Magnetic Stimulation (rTMS) has significantly improved for Treatment-Resistant Depression (TRD) in adults and promising evidence suggesting safety and efficacy of rTMS in adolescents. These youth studies currently use outdated stimulation protocols, with most of them using treatments on a once/daily schedule. Given the prevalence, morbidity, and mortality associated with depression in adolescents, and considering that over 40% of adolescents do not respond to medications, a randomized controlled trial (RCT) to establish the safety and efficacy of new rTMS protocols for difficult-to-treat depression in adolescents is desperately needed.

This open-label randomized controlled trial will compare accelerated intermittent theta burst stimulation (iTBS) and standard once a day iTBS in adolescents with major depressive disorder (MDD). For this pilot trial, 10 adolescents (5 females, 5 males) with treatment-resistant depression will be recruited. Each participant will undergo a 30-40-minute magnetic resonance imaging (MRI) scan, after which they will receive iTBS applied to the left dorsolateral prefrontal cortex (DLPFC) once a day for 6 weeks (standard treatment) or for an accelerated duration of 3 times a day for 2 weeks. Symptoms will be assessed through clinical assessments as well as self-report questionnaires. Prior to treatment start each participant will complete the clinical assessments as well as the self-report questionnaires for a baseline measurement. The self-report measures will be completed every 5th treatment (total of 7 times including baseline). The clinical assessments will be completed after the 15th and 30th treatment, as well as 2-,4-, and 12-weeks post treatment course (total of 6 times including baseline). The main outcome of this trial is a clinical response rate which will be defined as a ≥ 50% reduction in depressive symptoms based off of the Children's Depression Rating Scale Revised for depression (CDRS-R). The secondary outcome of this trial is suicidal ideation which will be measured by the Beck Scale for Suicidal Ideation (BSS), as well as several other outcomes such as anxiety, sleep quality, physical activity and stress. The ultimate goal of this study is to provide initial evidence for conducting a large-scale, randomized, multisite, placebo-controlled clinical trial evaluating the effects of an fMRI-guided accelerated rTMS protocol vs. standard once/daily rTMS for treatment-resistant depression in adolescents.
Intact autophagy-lysosomal pathway (ALP) in neuronal survival is crucial. However, it remains unclear whether ALP is intact after subarachnoid hemorrhage (SAH). Ten-eleven translocation (TET) 3 primarily regulates genes related to autophagy in neurons in neurodegenerative diseases. This study aims to investigate the role of TET3 in the ALP following SAH. The results indicate that the ALP is impaired after SAH, with suppressed autophagic flux and an increase in autophagosomes. This is accompanied by a decrease in TET3 expression. Activation of TET3 by α-KG can improve ALP function and neural function to some extent. Silencing TET3 in neurons significantly inhibited the ALP function and increased apoptosis. Inhibition of miR-93-5p, which is elevated after SAH, promotes TET3 expression. This suggests that the downregulation of TET3 after SAH is, at least in part, due to elevated miR-93-5p. This study clarifies the key role of TET3 in the functional impairment of the ALP after SAH. The preliminary exploration revealed that miR-93-5p could lead to the downregulation of TET3, which could be a new target for neuroprotective therapy after SAH.
The present invention relates to a multimedia medical data and diagnosis apparatus and method using a personal health record (PHR). According to the present invention, the multimedia medical data to be read from a read request terminal is received. The received multimedia medical data is transmitted to a read terminal selected by the read request terminal. The read result for the multimedia medical data is received and stored. The read result is transmitted to the read request terminal. So, the remote reading of the PHR can be enabled even in non-medical institutions.
PURPOSE:To provide a fluorescent and phosphorescent manicure enamel emitting bright light in light place as well as dark place, by mixing a fluorescent pigment and a phosphorescent pigment in clear manicure enamel. CONSTITUTION:The objective fluorescent and phosphorescent manicure enamel can be produced by mixing a clear manicure enamel with a fluorescent pigment 2 and a phosphorescent pigment 1 (e.g. luminous pigment, light-accumulating pigment, etc.) separately or attaching the former pigment to the surface of the latter pigment. The clear manicure enamel 3 is a nitrocellulose-based liquid such as cellulose nitrate lacquer, acrylic lacquer, etc. Since the enamel has high specific gravity, both pigments are mixed homogeneously with each other in a state that the phosphorescent pigment particle is encircled with the fluorescent pigment particles having smaller particle size. Accordingly, the product emits extremely bright color having a luminance brighter than any of Munsell color standard tablets in light place such as under the sunlight or a fluorescent lamp. In a dark place, the fluorescent pigment particles 2 encircling the phosphorescent pigment 1 emit bright fluorescent color excited by the light emitted from the phosphorescent pigment.
BACKGROUND: Malaria in pregnancy remains a major public health problem in the globe, especially in sub-Saharan Africa. In malaria endemic areas, most pregnant women remain asymptomatic, but malaria could still cause complications on the mother and her offspring; as well as serve as reservoirs to transmit infection. Despite these effects, no attention is given to the diagnosis of asymptomatic Plasmodium infections (APIs) using highly sensitive and specific laboratory diagnostic tools in Ethiopia. Therefore, the goal of this study was to compare the performance of Rapid Diagnostic Test (RDT), microscopy and real-time polymerase chain reaction (RT-PCR) to detect APIs among pregnant women.
METHODS: A health facility based cross -sectional study was conducted among pregnant women attending antenatal care at Fendeka town health facilities Jawi district, northwest Ethiopia from February to March, 2019. A total of 166 participants were enrolled by using convenient sampling technique. Socio-demographic features were collected using a semi structured questionnaire. Dried blood spot (DBS) samples were collected for molecular analysis. Asymptomatic Plasmodium infection on pregnant women was diagnosed using RDT, microscopy and RT-PCR. Descriptive statistics were used to determine the prevalence of APIs. Method comparison was performed, and Cohen's kappa coefficient (k) was used to determine the degree of agreement among the diagnostic methods. Parasite densities were also calculated.
RESULTS: The prevalence of API was 9.6%, 11.4% and 18.7% using RDT, microscopy and RT-PCR, respectively. The overall proportion of API was 19.3%. Sensitivity of the RDT was 83.3% as compared with microscopy. Rapid Diagnostic Test and microscopy also showed sensitivity of 50% and 60%, respectively, as compared with RT-PCR. The mean parasite density was 3213 parasites/µl for P falciparum and 1140 parasites/µl of blood for P. vivax.
CONCLUSION: Prevalence of API in the study area was high. Both RDT and microscopy had lower sensitivity when compared with RT-PCR. Therefore, routine laboratory diagnosis of API among pregnant women should be given attention and done with better sensitive and specific laboratory diagnostic tools.
BACKGROUND: Blood pressure readings taken before anesthesia often influence the decision to delay or cancel elective surgeries. However, the implications of these specific blood pressure values, especially how they compare to baseline, on postoperative in-hospital 30-day mortality remain underexplored. This research aimed to examine the effect of discrepancies between the baseline blood pressure evaluated in the ward a day before surgery, and the blood pressure observed just before the administration of anesthesia, on the postoperative mortality risks.
METHODS: The study encompassed 60,534 adults scheduled for non-cardiac surgeries at a tertiary care center in Seoul, Korea. Baseline blood pressure was calculated as the mean of the blood pressure readings taken within 24 hours prior to surgery. The preanesthetic blood pressure was the blood pressure measured right before the administration of anesthesia. We focused on in-hospital 30-day mortality as the primary outcome.
RESULTS: Our research revealed that a lower preanesthetic systolic or mean blood pressure that deviates by 20 mmHg or more from baseline significantly increased the risk of 30-day mortality. This association was particularly pronounced in individuals with a history of hypertension and those aged 65 and above. Higher preanesthetic blood pressure was not significantly associated with an increased risk of 30-day mortality.
CONCLUSION: We found that a lower preanesthetic blood pressure compared to baseline significantly increased the 30-day postoperative mortality risk, whereas a higher preanesthetic blood pressure did not. Our study emphasizes the critical importance of accounting for variations in both baseline and preanesthetic blood pressure when assessing surgical risks and outcomes.
Foscarnet Sodium Injection should be used with caution in patients with abnormal renal function because reduced plasma clearance of foscarnet will result in elevated plasma levels (see CLINICAL PHARMACOLOGY). In addition, Foscarnet Sodium Injection has the potential to further impair renal function (see WARNINGS). Safety and efficacy data for patients with baseline serum creatinine levels greater than 2.8 mg/dL or measured 24-hour creatinine clearances < 50 mL/min are limited. 

Renal function must be monitored carefully at baseline and during induction and maintenance therapy with appropriate dose adjustments for Foscarnet Sodium Injection as outlined below (see Dose Adjustment and PATIENT MONITORING). During Foscarnet Sodium Injection therapy if creatinine clearance falls below the limits of the dosing nomograms (0.4 mL/min/kg), Foscarnet Sodium Injection should be discontinued, the patient hydrated, and monitored daily until resolution of renal impairment is ensured. 

Foscarnet Sodium Injection is not recommended in patients undergoing hemodialysis because dosage guidelines have not been established.
Healthy cynomolgus macaques administered 3 intravenous doses or 3 SC doses of 40 mg/kg raxibacumab once every 12 days, or a single intramuscular dose (40 mg/kg) of raxibacumab, showed no adverse effects, including no effects up to 120 days post-dosing.

Studies with raxibacumab in rabbit, cynomolgus macaque, and human donor tissues showed no cross reactivity with brain.

Anthrax-infected rabbits and monkeys administered an intravenous injection of raxibacumab (40 mg/kg) at time of PA toxemia reproducibly showed greater severity of central nervous system (CNS) lesions (bacteria, inflammation, hemorrhage, and necrosis) in non-surviving animals compared with dead placebo-control animals, with no difference in mean time to death from spore challenge. The raxibacumab monoclonal antibody appears unable to penetrate the CNS until compromise of the blood-brain barrier (BBB) during the later stages of anthrax infection. The most severe brain lesions in rabbits were associated with bacteria and raxibacumab tissue binding in a similar pattern as endogenous IgG antibody that leaked across the compromised BBB. No dose/exposure-response relationship for brain histopathology was identified. Surviving rabbits and monkeys at the end of the 28-day studies showed no microscopic evidence of CNS lesions. CNS toxicity was not observed in healthy monkeys administered raxibacumab (40 mg/kg) or in GLP combination treatment studies with antibacterials in rabbits (levofloxacin) or in monkeys (ciprofloxacin) at any time.
Start fluvoxamine 50mg capsule once, then 100mg twice daily. May reduce dose for tolerability reasons. Will be followed in the RCT for approximately 15 days.
In the galectin family, a group of lectins is united by their evolutionarily conserved carbohydrate recognition domains. These polypeptides play a role in various cellular processes and are implicated in disease mechanisms such as cancer, fibrosis, infection, and inflammation. Following synthesis in the cytosol, manifold interactions of galectins have been described both extracellularly and intracellularly. Extracellular galectins frequently engage with glycoproteins or glycolipids in a carbohydrate-dependent manner. Intracellularly, galectins bind to non-glycosylated proteins situated in distinct cellular compartments, each with multiple cellular functions. This diversity complicates attempts to form a comprehensive understanding of the role of galectin molecules within the cell. This review enumerates intracellular galectin interaction partners and outlines their involvement in cellular processes. The intricate connections between galectin functions and pathomechanisms are illustrated through discussions of intracellular galectin assemblies in immune and cancer cells. This underscores the imperative need to fully comprehend the interplay of galectins with the cellular machinery and to devise therapeutic strategies aimed at counteracting the establishment of galectin-based disease mechanisms.
A three-dimensional (3D) density volume of an object is constructed from tomography images (e.g., x-ray images) of the object. The tomography images are projection images that capture all structures of an object (e.g., human body) between a beam source and imaging sensor. The beam effectively integrates along a path through the object producing a tomography image at the imaging sensor, where each pixel represents attenuation. A 3D reconstruction pipeline includes a first neural network model, a fixed function backprojection unit, and a second neural network model. Given information for the capture environment, the tomography images are processed by the reconstruction pipeline to produce a reconstructed 3D density volume of the object. In contrast with a set of 2D slices, the entire 3D density volume is reconstructed, so two-dimensional (2D) density images may be produced by slicing through any portion of the 3D density volume at any angle.
1,224,772. Fluorine - containing ethers. ALLIED CHEMICAL CORP. 25 April, 1968 [25 April, 1967 (2)], No. 19752/68. Heading C2C. [Also in Division C5] Novel ethers of the formula wherein each R 1  is independently a fluorine or chlorine atom or a C 1-9  optionally halosubstituted alkyl group, provided that not more than two are alkyl groups, or two R 1 s form a C 1-18  optionally halo - substituted alkylene radical; A is a radical of the formula where R 3  and R 4  are hydrogen or chlorine atoms or alkyl groups, R 5  and R 6  are hydrogen or fluorine atoms, R 7  is a hydrogen, fluorine, chlorine or bromine atom or a perfluoroalkyl group and p is from 1 to 9, provided that when R 6  and R 7  are both fluorine atoms R 5  is also a fluorine atom; C and D are independently divalent radicals derivable from unsaturated compounds; m and n are from 0 to 75; v is 0 or 1; and E is a hydrogen or halogen atom, provided that when E is a bromine atom no other bromine atom is present, or E is a radical where u is from 1 to 6, provided that when v is zero the carbon atom adjacent to the sulphate group bears at least one hydrogen atom and provided that, when E is hydrogen or halogen, m+n+v is at least 1; are prepared (1) when v=0 by telomerizing a bromide or iodide of the formula where E is bromine or iodine with one or two olefinic or acetylenic compounds or (2) when v is 1, by converting the corresponding compound in which E is an OH group into a bromide or iodide, and in each case if desired replacing the bromine or iodine atom by a hydrogen, chlorine. or fluorine atom or reacting the compound with SO 3 . Bactericidal and bacteristatic agents, e.g. salves and ointments contain lower telomer iodides of the above formula as active ingredients, E being an iodine atom and m + n being from 1 to 5. Reference has been directed by the Comptroller to Specification 1,142,306.
<P>PROBLEM TO BE SOLVED: To provide a method for preparing active oxygen species which can be generated efficiently and easily, a method for purifying a matter to be purified efficiently and easily, and a therapeutic agent for cancer useful for treating non-invasive cancer.  <P>SOLUTION: The active oxygen species is prepared by irradiating a coiled carbon fiber with ultrasonic waves while the coiled carbon fiber is dispersed or placed in a generated liquid containing water. The method for purifying the matter to be purified applies the method for preparing the active oxygen species. The matter to be purified is purified by irradiating the coiled carbon fiber with ultrasonic waves while the coiled carbon fiber is dispersed or placed in a purification liquid containing water and the matter to be purified. The therapeutic agent for cancer contains the coiled carbon fiber as an active ingredient, is constituted to be administered in a human body and to generate the active oxygen species in a human body by the irradiation with ultrasonic waves, and is prepared by applying the method for preparing the active oxygen species.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
PURPOSE: A method for improving the antioxidative activity of a natural drug material extract is provided to enhance the concentration of antioxidative ingredients such as phenol and flavonoid. CONSTITUTION: A method for improving the antioxidative activity of a natural drug material extract comprises: a step of culturing Leuconostoc sp. isolated from kimchi in a medium containing a mixture containing extracts of ginseng or red ginseng, Houttuynia cordata, Morus alba L., and Schisandra chinensis Baillon; and a step of collecting the fermented liquid of the natural drug materials. The medium is a mineral medium(MM) containing 3g of K2HPO4, 0.01g of FeSO_4·H_2O, 0.01g of MnSO_4·7H_2O, 0.01g of NaCl, 0.05g of CaCO_3, 0.1g of ethylene diamine tetraacetic acid(EDTA). The Leuconostoc sp. is Leuconostoc citreum JYY-17(deposit number KACC91520P). [Reference numerals] (AA) ABUS radical(control group %)
They will start walking the day of surgery. Levobupivacain 5mg/ml will be placed in the knee tissues. Tranexamic acid inside the knee. No drains.
Elevated homocysteine (Hcy) levels, referred to hyperhomocysteinemia, are associated with an increased risk of several neurological disorders. Ferroptosis and inflammation play a vital role in Hcy-induced neuronal dysfunction. Amentoflavone (AMF), an active natural biflavone compound, exhibits antioxidative, anti-inflammatory, and neuroprotective activities. This study aimed to explore the potential effects of AMF on Hcy-induced neuronal injury, with a particular focus on the underlying mechanisms involving ferroptosis and inflammation. We assessed neuronal damage in HT22 cells by measuring cell viability, lactate dehydrogenase (LDH) release, and proliferation rates. Additionally, we evaluated oxidative stress markers including the levels of reactive oxygen species (ROS), MitoSOX, mitochondrial membrane potential (MMP), malondialdehyde (MDA), and glutathione (GSH). Iron metabolism and ferroptosis-related gene expressions (Ptgs2, Tfr1, and Fth1) were quantified. TheSLC7A11/GPX4 axis was also detected. Our results showed that AMF treatment dramatically mitigated Hcy-induced neuronal injury by increasing cell viability, decreasing LDH release, and promoting cell proliferation. AMF treatment also reduced Hcy-induced oxidative stress and lipid peroxidation, as evidenced by reduced ROS, MitoSOX, MMP, and MDA levels, along with an increased GSH content in HT22 cells. In addition, AMF treatment reduced iron content and ferroptosis-related gene mRNA levels. However, Erastin, a ferroptosis inducer, blocked these neuroprotective effects of AMF. Ferroptosis inhibitor Ferrostatin-1 also attenuated Hcy-induced ferroptosis. Moreover, both AMF and Ferrostatin-1 effectively mitigated Hcy-induced inflammation, which was again antagonized by Erastin. Mechanistically, AMF treatment enhanced SLC7A11/GPX4 axis in Hcy-treated HT22 cells. In conclusion, these findings suggest that AMF possesses neuroprotection against Hcy-induced injury primarily by inhibiting ferroptosis-mediated inflammation, partly through the activation of SLC7A11/GPX4 axis.
It is an open label study, designed with 14 patients, men and women, from 18 to 60 years old, hospitalized for a characterized depressive episode (as defined by International Classification of Diseases version 10 criteria). They have to be refractory to an antidepressant treatment prescribed in primary care medicine and have a Dexamethasone Suppression Test (DTS) non-suppression status. All patients included will take the association of SSRI/SNRI and METYRAPONE for 28 days.
An agent is provided for magnetic resonance imaging (MRI). The agent uses chemical exchange of heavy hydrogen on comparing MRI images. An isotonic-pressure normal saline solution with deuterium oxide (D2O) is made. The solution is used for obtaining the MRI images through intravenous injection. An exchange between hydrogen and deuterium happens and thus a solution of hydrogen deuterium oxide (HDO) is obtained. After such an exchange, MRI images are compared for differences. Thus, a novel, non-radioactive, non-toxic and non-invasive MRI agent is provided for people who are allergic to general imaging agents.
This study is a randomized controlled trial and held in Cipto Mangunkusumo Hospital.

Pregnant women 28-34 weeks of gestational age, who fulfill the inclusion criteria, divide into two groups. Subjects from both groups receive the hospital protocol of preterm birth, 4 doses of 6 mg of dexamethasone, intravenous 12 hours apart to support lung maturation. Subjects in intervention group receive oral single-dose beta-carotene 25,000 IU, oral single-dose vitamin D3 50,000 IU and oral zinc 50 mg/day for 3 days. The maternal dan cord blood sample are obtained for zinc, vitamin A and 25(OH)D levels before and after intervention. After the premature neonates was born, observation will be done for maximum period of 4 weeks. The presence and severity of HMD and feeding intolerance or NEC will be recorded. Neonates showing any signs of HMD and/or abdominal distension will need to undergo additional chest/abdominal x-ray procedures.
The invention provides a lansoprazole composition for injection, and relates to the technical field of medicine manufacturing. The main medicine of the composition comprises lansoprazole and melatonin, wherein the melatonin comprises a quick release part and a cyclodextrin-included slow release part. According to the lansoprazole composition for injection provided by the invention, the therapeutic effect of the product is improved, instability caused by oral administration of melatonin is avoided and melatonin is quick to distribute and eliminate and the like, and the first pass effect of melatonin is reduced. The dosage of melatonin is reduced. The design of dosage combining quick release and slow release is in accordance with secretion characteristic of melatonin, so that the problem of half-life period of melatonin is solved and the bioavailability of a product is improved. The composition has the synergistic effect for treating gastric ulcer by lansoprazole, and lansoprazole and melatonin are combined to not only treat gastric ulcer, but also accelerate ulcer healing, so that the therapeutic effect of lansoprazole to gastric ulcer is improved. The course of treatment is shortened, the use level of lansoprazole is further reduced, the side effect of lansoprazole is reduced, and the immunity of a human body can be improved.